The Endocannabinoid System Explained: Why Cannabis Works in Your Body

The endocannabinoid system is a cell-signaling network that was discovered in the early 1990s by researchers studying how THC interacts with the human body. Israeli chemist Dr. Raphael Mechoulam and his colleagues identified the first endocannabinoid, anandamide, in 1992. What they found stunned the scientific community: the human body produces its own cannabis-like compounds and has an entire receptor system designed to use them.

The ECS exists in all mammals, not just humans. Dogs, cats, horses, and every other mammalian species has one. It operates whether or not you ever consume cannabis. Your body is constantly producing endocannabinoids, activating receptors, and breaking down those compounds as part of a continuous cycle that keeps critical functions in balance. The word “endocannabinoid” literally means “cannabinoid made within” — your body manufactures these molecules on demand.

Think of the ECS as your body’s master regulator. When something falls out of balance — your temperature rises, your stress level spikes, you experience pain — the ECS activates to help bring things back to a stable state. Scientists call this homeostasis, and maintaining it is the primary function of the endocannabinoid system.

CB1 receptors are densely concentrated in the brain and central nervous system. They are found in especially high numbers in the hippocampus (memory), the basal ganglia (movement), the cerebral cortex (higher thinking), the cerebellum (coordination), and the hypothalamus (appetite). This distribution explains virtually every effect that THC produces: altered memory, changes in perception, increased appetite, altered coordination, and the subjective experience of being “high.”

CB1 receptors are also found in smaller numbers in the spinal cord, peripheral nerves, liver, thyroid, uterus, bones, and skin. This wider distribution means the ECS influences far more than just brain function. Pain signals traveling through the spinal cord, for example, are modulated by CB1 receptors along the way.

CB2 receptors were identified in 1993, just one year after anandamide was discovered. They are found in high concentrations on immune cells, in the spleen, in the gastrointestinal system, and in peripheral tissues throughout the body. Unlike CB1 receptors, CB2 receptors do not produce psychoactive effects when activated. Instead, they are primarily involved in modulating inflammation, immune response, and tissue repair.

This distinction is critical for understanding why different cannabis products produce different effects. A high-THC product primarily activates CB1 receptors in the brain. A CBD-rich product primarily influences CB2 receptor activity in the immune system and gut. A balanced THC:CBD product interacts with both receptor types simultaneously. This is one reason budtenders ask what you are looking to achieve — different goals require targeting different receptors.

When you inhale cannabis smoke or vapor, THC enters your bloodstream through the lungs and reaches your brain within seconds. Once there, it binds to CB1 receptors in the same spots where anandamide normally works. The molecular shape of THC is similar enough to anandamide that CB1 receptors accept it and activate. But there are two critical differences between THC and anandamide.

First, THC is a stronger activator. It binds to CB1 receptors more aggressively than anandamide, producing effects that are more intense than your body would generate naturally. Second, THC is not broken down as quickly. The enzyme FAAH that normally breaks down anandamide within seconds is less effective against THC, meaning the signal lasts much longer. This combination of stronger activation and longer duration is what produces the subjective experience of being high.

Unlike THC, CBD does not bind strongly to CB1 or CB2 receptors. It does not fit neatly into the receptor like a key in a lock. Instead, CBD works through at least three distinct mechanisms that modulate the endocannabinoid system indirectly. This is why CBD does not produce a high: it never directly activates the CB1 receptors in your brain the way THC does.

Think of it this way: if THC is a musician who grabs the microphone and starts singing, CBD is the sound engineer who adjusts the mixing board. CBD does not perform directly — it changes how the entire system operates. This makes CBD’s effects subtler and broader, which is why it is being researched for such a wide variety of potential applications.

First proposed by Dr. Raphael Mechoulam and Dr. Shimon Ben-Shabat in 1998, the entourage effect describes how the full spectrum of cannabis compounds — cannabinoids, terpenes, flavonoids, and other plant chemicals — work together synergistically within the endocannabinoid system. The total effect of these compounds working together is greater than the sum of their individual effects.

Cannabis contains over 100 cannabinoids, 150+ terpenes, and dozens of flavonoids. Each of these compounds interacts with the ECS or related systems in some way. Terpenes like myrcene may enhance THC’s ability to cross the blood-brain barrier. Limonene may increase serotonin activity alongside CBD. Caryophyllene is unique among terpenes because it directly activates CB2 receptors, making it a functional cannabinoid as well as a terpene. For a deeper dive into terpenes, read our complete cannabis terpenes guide.

In 2001, neurologist Dr. Ethan Russo published a groundbreaking paper proposing that some people may produce insufficient endocannabinoids, resulting in a systemic regulatory failure. If the ECS is supposed to maintain homeostasis across pain, mood, sleep, digestion, and immune function, then an underperforming ECS would theoretically produce problems in multiple areas simultaneously.

Dr. Russo specifically linked CED to three conditions that are notoriously difficult to treat and share overlapping symptoms: migraines, fibromyalgia, and irritable bowel syndrome (IBS). All three involve pain processing dysfunction, all three commonly co-occur in the same patients, and all three have been resistant to conventional treatments. The theory suggests that these conditions may share a common underlying cause: an ECS that is not producing enough endocannabinoids to regulate the body properly.

A 2016 follow-up review by Dr. Russo found that over a decade of additional research had strengthened the case for CED. Animal studies showed that reduced endocannabinoid signaling produced symptoms consistent with all three conditions. Human studies found lower anandamide levels in migraine patients and altered endocannabinoid levels in fibromyalgia patients. While CED has not been fully established as a clinical diagnosis, the evidence continues to accumulate.

This framework also explains why the same product can affect two people differently. Everyone’s endocannabinoid system is unique. Your CB1 receptor density, your natural endocannabinoid production rate, your enzyme efficiency, and even your genetic variations all influence how you respond to any given cannabis product. This is why our budtenders always ask about your experience level and what you have tried before — your personal history with cannabis tells us a lot about how your specific ECS responds.